New hope for lung cancer patients after targeted therapy fails: BL-B01D1 takes on chemo in phase 3 trial
NCT ID NCT06382116
First seen Nov 17, 2025 · Last updated May 20, 2026 · Updated 20 times
Summary
This phase 3 study compares a new drug, BL-B01D1, with standard chemotherapy in 432 adults with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to EGFR-targeted pills. The main goal is to see if BL-B01D1 can delay cancer growth or death better than chemo. Participants must not have had any other cancer treatment besides the EGFR pills.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.